
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZDHHC24 (zDHHC palmitoyltransferase 24) encodes a membrane-associated palmitoyltransferase predicted to catalyze protein-cysteine S-palmitoylation. It is predicted to function in protein targeting to membranes and may be active in the Golgi apparatus and endoplasmic reticulum. These predicted activities suggest a role in regulating protein localization and membrane-associated cellular processes through lipid modification.
NCI-H1975 is a human non-small cell lung cancer cell line established from lung tumor tissue. The donor was a non-smoker. The cell line is used as a model for studying lung cancer biology and molecular mechanisms associated with non-small cell lung carcinoma.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_001348571
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?